|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,089 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mayes Gregory T. |
Chief Operating Officer |
|
2016-04-29 |
4 |
A |
$7.74 |
$2,183 |
D/D |
282 |
121,316 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-04-29 |
4 |
D |
$7.74 |
$4,698 |
D/D |
(607) |
316,054 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-04-29 |
4 |
A |
$7.74 |
$9,451 |
D/D |
1,221 |
316,661 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-03-31 |
4 |
D |
$9.03 |
$2,483 |
D/D |
(275) |
315,440 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-03-31 |
4 |
A |
$9.03 |
$9,445 |
D/D |
1,046 |
315,715 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-03-31 |
4 |
D |
$9.03 |
$461 |
D/D |
(51) |
80,445 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-03-31 |
4 |
A |
$9.03 |
$2,041 |
D/D |
226 |
80,496 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-03-31 |
4 |
D |
$9.03 |
$488 |
D/D |
(54) |
121,034 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-03-31 |
4 |
A |
$9.03 |
$2,185 |
D/D |
242 |
121,088 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-03-31 |
4 |
S |
$9.13 |
$30,357 |
D/D |
(3,325) |
127,731 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-03-31 |
4 |
D |
$9.03 |
$975 |
D/D |
(108) |
131,056 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-03-31 |
4 |
A |
$9.03 |
$2,276 |
D/D |
252 |
131,164 |
|
- |
|
Mckearn Thomas J |
Director |
|
2016-03-16 |
4 |
S |
$8.25 |
$115,500 |
D/D |
(14,000) |
86,220 |
|
- |
|
Ridge Thomas J |
Director |
|
2016-03-03 |
4 |
A |
$7.35 |
$36,750 |
D/D |
5,000 |
24,306 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-02-29 |
4 |
D |
$5.46 |
$333 |
D/D |
(61) |
130,912 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-02-29 |
4 |
A |
$5.46 |
$2,271 |
D/D |
416 |
130,973 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-02-29 |
4 |
D |
$5.46 |
$480 |
D/D |
(88) |
120,846 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-02-29 |
4 |
A |
$5.46 |
$2,184 |
D/D |
400 |
120,934 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-02-29 |
4 |
D |
$5.46 |
$453 |
D/D |
(83) |
80,270 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-02-29 |
4 |
A |
$5.46 |
$2,037 |
D/D |
373 |
80,353 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-02-29 |
4 |
D |
$5.46 |
$2,484 |
D/D |
(455) |
314,669 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-02-29 |
4 |
A |
$5.46 |
$9,446 |
D/D |
1,730 |
315,124 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-02-24 |
4 |
S |
$5.58 |
$83,906 |
D/D |
(15,037) |
79,980 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-01-29 |
4 |
D |
$6.82 |
$593 |
D/D |
(87) |
120,534 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2016-01-29 |
4 |
A |
$6.82 |
$2,128 |
D/D |
312 |
120,621 |
|
- |
|
465 Records found
|
|
Page 8 of 19 |
|
|